miR-552 can down-regulate the expression of SMAD2, and the low expression of miR-552 and the high expression of SMAD2 can play a synergistic role to promote 5-FU resistance of cancer cells, which is not conducive to the treatment of CRC 2. Here, SMAD2 is linked to colorectal carcinoma.